Literature DB >> 28660898

Chinese biopharma starts feeding the global pipeline.

Asher Mullard.   

Abstract

Mesh：

Year:  2017        PMID： 28660898     DOI： 10.1038/nrd.2017.94

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

Review 1.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

2.  Biologics for Non-Cancer Dermatological Diseases: Analysis on China's Clinical Trial Registration Trend From 2016 to 2020.

Authors:  Beibei Zhu; Yi Liu; Jing Li; Qi Ni; Zheng Yin; Junli Zhu; Ken Chen; Xueyuan Yang
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

3.  Guzhi Zengsheng Zhitongwan, a Traditional Chinese Medicinal Formulation, Stimulates Chondrocyte Proliferation through Control of Multiple Genes Involved in Chondrocyte Proliferation and Differentiation.

Authors:  Baojin Yao; Bocheng Lu; Hongwei Gao; Mei Zhang; Xiangyang Leng; Daqing Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-12       Impact factor: 2.629
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.